At a Glance
For vaccine applications, we build immune modulation strategies compatible with mRNA-LNP: improving immune quality and protective efficacy within safety boundaries, covering infectious disease vaccines and tumor/therapeutic vaccines.
With vaccine efficacy as the goal, safety boundaries as the baseline, and interpretability and regulatory readiness as constraints, we build an immune modulation system co-designed with mRNA-LNP.
What We Do
Immune modulation is not simply stacking stimuli—it is engineering the "strength, timing, and location of immune signals" on top of mRNA expression kinetics and delivery distribution, to achieve higher-quality, more durable, and predictable immune protection.
We focus on adjuvant formats and co-delivery strategies compatible with mRNA-LNP, supporting both infectious disease vaccine enhancement and cellular immune shaping for tumor/therapeutic vaccines, with safety and regulatory readiness built in as equal constraints.
Compatible Adjuvant Formats
Compatibility emphasis: co-designed with expression, delivery, and safety boundaries
Immune signals and mRNA enter key immune cells via the same pathway, improving synergy and predictability while reducing "stimulus-expression" misalignment.
Moderately decoupling immune stimulation from expression avoids excessive inflammatory peaks or translational inhibition, widening the safety boundary.
Establishing a favorable immune microenvironment at the injection site and draining lymph nodes to promote key immune processes while reducing systemic exposure.
Immune Targets & Application Scenarios
Efficacy-driven humoral immune enhancement, complemented by cellular immune reinforcement.
- Improve neutralizing antibody quality and breadth to support variant/lineage updates
- Promote germinal center formation and immune durability, enhancing memory and booster benefits
- Maintain predictable protection thresholds across diverse populations and pre-existing immunity backgrounds
Cellular immune quality as the core focus, with emphasis on safety boundaries and repeatability.
- Shape antigen-specific T cell functionality, persistence, and tissue infiltration capability
- Reduce off-target inflammation and systemic toxicity, widening the therapeutic window and improving tolerability
- Co-optimize with delivery/expression to avoid "immune activation–expression inhibition" conflicts
Standardized Evaluation & Data Delivery
Establish comparable signal profiles across key time windows, controlling peaks, duration, and pathway characteristics.
Antibody function and isotyping, T cell phenotype/function and memory trends—forming an interpretable quality framework.
Focus on off-target inflammation, local reactions, and repeat-dosing feasibility to support broader population strategies.
Use traceable evidence to explain "why it works better," providing a consistent basis for clinical plans and regulatory communication.
What We Deliver
Define immune targets by indication/population/dosing strategy, matched to compatible adjuvant formats and engineering pathways.
Standardized readouts and comparative frameworks forming reusable data assets and decision-making evidence.
Integration with mRNA molecular engineering, delivery systems, and CMC to deliver actionable engineering and regulatory pathways.
